Cosmic, It seems that we have been the recipient of divergent information in regards to the capabilities of the platform.
As you have stated there was some mention that studies could be accomplished given a couple of hundred thousand dollars and a six month time frame. The now moribund CMIH deal was along those lines.
However to suggest that such a study could result in a viable classifier, flies in the face of our own experiences. Statnome has been around for many multiples of six months and has had a lot more than a few hundred dollars available during that timeframe, and yet is still to see the light of day.
If such a program were available (and was also credible) it would be inconceivable that the pharmas would not take advantage of it. They spend more than that on a 30 second ad during a Seinfeld rerun.
Barring an update from the company, we can only assume that the offer is no longer available or it was not credible to begin with, being either more costly, of longer duration or simply ineffective.
regards,
frog
News 
Market Data 
Discover 
AI
